← Leaderboards
Miguel Villalona
Ohio State University
$4,381,136
Attributed
$4,381,136
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2011–15$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$4,381,136 · 1
By mechanism
N01$4,381,136 · 1
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- David P Carbone$20,647,321
- Rama K Mallampalli$45,256,042
- Michael R Grever$17,739,693
- Paulus Ml Janssen$9,312,933
- Fedias L. Christofi$6,846,539
Others in their field
Top investigators on “Clinically Relevant”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$347,663,527
- Chanza Baytop · Westat, Inc.$271,217,917
- Lawrence Corey · Fred Hutchinson Cancer Center$225,946,688
- Barton F Haynes · Duke University$218,783,682
Research focus
Clinically RelevantClinical TrialsCombined Modality TherapyContractsData ReportingDevelopmental Therapeutics ProgramDrug DevelopmentDrug IndustryMolecular TargetPhase 2 StudyProtocols DocumentationResearch PersonnelTherapeutic DevelopmentToxic Effect
Grant awards (5)
TAS::75 0849::TAS EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$656,324
N01 · FY2015 · CA · contact PI
TAS::75 0849::TAS EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$1,195,983
N01 · FY2014 · CA · contact PI
TAS::75 0849::TAS EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$1,067,801
N01 · FY2013 · CA · contact PI
TAS::75 0849::TAS EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$1,120,585
N01 · FY2012 · CA · contact PI
TAS::75 0849::TAS EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$340,443
N01 · FY2011 · CA · contact PI